pSivida’s treatment for chronic diabetic macular edema awaits FDA approval
02 April, 2013pSivida licensee Alimera Sciences has made a resubmission to the US Food and Drug Administration for approval of Iluvien for chronic diabetic macular edema.
Partnership to further develop anticancer formulation
28 March, 2013The University of Wollongong (UOW) has licensed the commercialisation rights to a novel drug formulation for the treatment of metastatic colorectal cancer (mCRC) to a local biotech company - FivePhusion.
Stem cells and business development feature in March AusBiotech journal
28 March, 2013AusBiotech is pleased to provide the latest edition of the Australasian Biotechnology e-journal (Volume 23, Number 1).
Bioniche welcomes Canadian investments in R&D
28 March, 2013Bioniche (ASX:BNO) has lauded decisions by the Canadian government to provide more funding for programs which support R&D and commercialisation efforts by the nation’s companies.
AusBiotech appoints global life sciences fund manager as new board member
26 March, 2013AusBiotech has announced the appointment of Lawrence Gozlan as a non-executive director, bringing to the board global capital markets experience and specialist knowledge in life sciences investing.
Driving innovation
26 March, 2013 by Dr Anna Lavelle, CEO, AusBiotechAusBiotech welcomes the federal government’s Plan for Australian Jobs, which will aid innovative companies and help support the biotechnology sector.
Strong early results from Viralytics melanoma trial
25 March, 2013 by Dylan Bushell-EmblingA lead investigator for Viralytics’ (ASX:VLA) phase II trial of Cavatak in melanoma has presented some preliminary results from his leg of the study.
pSivida partner to resubmit Iluvien NDA this month
25 March, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) has said partner Alimera plans to resubmit Iluvien for US approval in March and that it will receive a $23.9 million milestone payment if the NDA is accepted.
Phosphagenics’ new opioid patch clears phase I
25 March, 2013 by Dylan Bushell-EmblingPhosphagenics’ (ASX:POH) TPM-Oxymorphone patch, its second opioid-based pain patch in development, has met its delivery targets in a phase I trial.
Phylogica gets Australian Phylomer patent
25 March, 2013 by Dylan Bushell-EmblingPhylogica (ASX:PYC) has won an Australian patent covering its Phylomer peptide libraries as a composition of matter.
Melanoma trial recruitment accelerating
22 March, 2013 by Dylan Bushell-EmblingViralytics (ASX:VLA) has signed on 12 patients in the last three months for its phase II trial of oncolytic virus Cavatak in patients with late-stage melanoma.
Alchemia appoints two new board members
22 March, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has added an oncology expert and an international investment banking veteran to its board.
Who’s who in biotech business development gather in Adelaide
21 March, 2013The Business Development Workshop and Forum has kicked off in Adelaide, with delegates keen to understand the changing landscape of licensing deal collaborations and what it means for business development in biotechnology companies.
iSonea unveils cloud asthma monitoring tool
20 March, 2013iSonea (ASX:ISN) has used an Asthma Foundation conference to unveil AsthmaSense Cloud, a system for cloud storage and transfer of wheeze monitoring data.
FDA rejects Pharmaxis’s NDA for Bronchitol
20 March, 2013 by Dylan Bushell-EmblingUS regulator FDA has told Pharmaxis (ASX:PXS) that it will likely need to conduct a new phase III trial before Bronchitol can be approved as a cystic fibrosis treatment.
